ClinicalTrials.gg
RecruitingNCT05816382Updated Mar 5, 2026

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

A Phase 2/3 interventional study of TAK-861 in Narcolepsy Type 1, sponsored by Takeda. Recruiting at 52 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Takeda · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Planned enrollment
Largest of 12
500 · median 95
Started
2023
with 2 others
Phase 2/3
Only one
of the 16
Registered
9th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 2/3, and was the 9th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.

Read the detailed description

The drug being tested in this trial is called TAK-861. TAK-861 is being tested to treat people who have narcolepsy type 1 (NT1). This trial will look at the safety of TAK-861 along with improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes.

This trial was initiated in parallel with the parent phase 2 trials, TAK-861-2001 (NCT05687903) and TAK-861-2002 (NCT05687916), which included participants with NT1 and narcolepsy type 2 (NT2), respectively. This long-term extension (LTE) trial enrolled participants with both diagnoses from the two phase 2 trials. As the TAK-861-2002 trial did not meet prespecified criteria, all participants with NT2 were discontinued, and moving forward this extension study only includes participants with NT1 who previously completed a parent trial. Parent trials include all TAK-861 phase 3 trials in addition to the phase 2 trial participants from TAK-861-2001.

The trial will enroll up to 500 participants. All participants in the trial will receive TAK-861. Participants who were previously on a placebo dose will be assigned to one of the TAK-861 doses randomly.

This multi-center trial will be conducted worldwide. Study period is approximately 5 years or until the study is stopped at the sponsor's discretion, or the product is approved and launched. Participants will make multiple visits to the clinic (with some visits optionally conducted by home health) and will have a follow-up assessment 4 weeks after the last dose of trial intervention.

03

Conditions studied

  • Narcolepsy Type 1

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Participant with a diagnosis of NT1 who has completed a controlled trial with TAK-861, and for whom the investigator has no clinical objection to their enrollment.

Exclusion criteria

Exclusion criteria:

  1. Participant has a treatment-emergent adverse event (TEAE) that remains severe at the time of rollover related to the trial intervention from the parent trial or discontinued because of TEAEs in the parent trial.
  2. Participant has a risk of suicide according to endorsement of item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
  3. The participant has (ALT) and aspartate aminotransferase (AST) values greater than (>) 1.5 times the (ULN).
  4. Participant has a current medical disorder, other than narcolepsy with or without cataplexy, associated with excessive daytime sleepiness (EDS).
  5. Participant has current active major depressive episode (MDE) or has had an active MDE in the past 6 months.
  6. Participant has developed (within the last 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
  7. Participant has epilepsy or history of seizure.
  8. Participant has any other medical condition, such as anxiety, depression, heart disease, or significant hepatic, pulmonary, or renal disease, that requires them to take excluded medications.
  9. Participant has a history of cerebral ischemia, (less than (\<) 5 years ago), or cerebral hemorrhage.
  10. Participant has a history of myocardial infarction, coronary artery disease, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.
  11. Participant has a history of cancer in the past 5 years.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    TAK-861

    In this trial, all participants are on TAK-861 treatment and they can switch to one of the available doses as needed.

    Drug: TAK-861

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One or More Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving trial intervention.

    Time frame: From signing the informed consent form up to follow-up of 4 weeks after the last dose (Up to approximately 5 years)

Secondary outcomes

  1. Change from Baseline in the Parent Trial in Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT)

    The MWT evaluates a person's ability to remain awake under soporific conditions. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions done 2 hours apart. Sleep latency in each session will be recorded. Participants will be required to stay awake in between the 4 sessions.

    Time frame: Baseline (parent trial), Week 26 (current LTE trial)

  2. Change from Baseline in the Parent Trial in Epworth Sleepiness Scale (ESS) Total Score

    The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.

    Time frame: Baseline (parent trial); Week 2 through Year 5 (current LTE trial)

  3. Change from Baseline in the Parent Trial in Weekly Cataplexy Rate (WCR) Using the Patient-reported Cataplexy Diary

    Participants will record episodes of cataplexy in the diary throughout the trial.

    Time frame: Baseline (parent trial); Year 1 through Year 5 (current LTE trial)

07

Study locations

52 of 52 sites recruiting
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
    Recruiting
  • Stanford Center for Sleep Sciences and Medicine
    Redwood City, California 94063, United States
    Recruiting
  • SDS Clinical Trials, Inc.
    Santa Ana, California 92705, United States
    Recruiting
  • Delta Waves LLC - Hunt - PPDS
    Colorado Springs, Colorado 80918, United States
    Recruiting
  • Florida Pediatric Research Institute
    Orlando, Florida 32803, United States
    Recruiting
  • Neurotrials Research
    Atlanta, Georgia 30342, United States
    Recruiting
  • Georgia Neuro Center
    Gainesville, Georgia 30501, United States
    Recruiting
  • Neurocare Inc
    Newton, Massachusetts 02459, United States
    Recruiting
  • Henry Ford Medical Center - Columbus
    Novi, Michigan 48377, United States
    Recruiting
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
    Recruiting
  • ARSM Research, LLC
    Huntersville, North Carolina 28078, United States
    Recruiting
  • CTI Research Center
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Intrepid Research
    Cincinnati, Ohio 45227, United States
    Recruiting
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
    Recruiting
  • Medical University of South Carolina - PPDS
    Charleston, South Carolina 29425, United States
    Recruiting
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201, United States
    Recruiting
  • Sleep Therapy and Research Center
    San Antonio, Texas 78229, United States
    Recruiting
  • Children's Specialty Group
    Norfolk, Virginia 23510, United States
    Recruiting
  • Woolcock Institute of Medical Research
    Glebe, New South Wales 2037, Australia
    Recruiting
  • Terveystalo Helsinki Sleep Clinic
    Helsinki, Uusimaa 00380, Finland
    Recruiting
  • Hopital Pierre-Paul Riquet
    Toulouse, Haute-Garonne 31000, France
    Recruiting
  • CHU Gui De Chauliac
    Montpellier, Herault 34090, France
    Recruiting
  • CHU de Grenoble
    La Tronche, Isere 38700, France
    Recruiting
  • Hopital de la Pitie Salpetriere
    Paris, 75013, France
    Recruiting
  • Universitaet Regensburg am Bezirksklinikum
    Regensburg, Bavaria 93053, Germany
    Recruiting
  • Somni Bene Institut fur Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19053, Germany
    Recruiting
  • Charite - Universitatsmedizin Berlin
    Berlin, 10117, Germany
    Recruiting
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
    Recruiting
  • Fondazione PTV Policlinico Tor Vergata
    Rome, Lazio 00133, Italy
    Recruiting
  • Istituto Neurologico Mediterraneo Neuromed
    Pozzilli, Molise 86077, Italy
    Recruiting
  • Ospedale Bellaria
    Bellaria, 40139, Italy
    Recruiting
  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
    Recruiting
  • Howakai Kuwamizu Hospital
    Kumamoto, Kumamoto 862-0954, Japan
    Recruiting
  • YOU ARIYOSHI Sleep Clinic
    Nagasaki, Nagasaki 850-0045, Japan
    Recruiting
  • Gokeikai Osaka Kaisei Hospital
    Osaka, Osaka 532-0003, Japan
    Recruiting
  • Koishikawa Tokyo Hospital
    Bunkyo-Ku, Tokyo 112-0012, Japan
    Recruiting
  • Aichi Medical University Hospital
    Nagakute, 480-1195, Japan
    Recruiting
  • Kempenhaeghe - PPDS
    Heeze, North Brabant 5591 VE, Netherlands
    Recruiting
  • Slaap-Waakcentrum SEIN Heemstede
    Heemstede, North Holland 2103 SW, Netherlands
    Recruiting
  • University of Oslo
    Oslo, 0450, Norway
    Recruiting
  • Hospital Universitario Araba Santiago
    Vitoria-Gasteiz, Alava 01009, Spain
    Recruiting
  • Hospital General de Castello
    Castellon, Castellon 12004, Spain
    Recruiting
  • Hospital de La Ribera
    Alzira, Valencia 46600, Spain
    Recruiting
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
    Recruiting
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain
    Recruiting
  • Hospital Vithas Madrid Arturo Soria
    Madrid, 28046, Spain
    Recruiting
  • Sahlgrenska University Hospital
    Gothenburg, Västra Götaland County 413 46, Sweden
    Recruiting
  • Klinik Barmelweid AG
    Barmelweid, Aargau (de) 5017, Switzerland
    Recruiting
  • Neurocenter of Southern Switzerland
    Lugano, Ticino (it) 6900, Switzerland
    Recruiting
  • Universitaetsspital Bern - Inselspital
    Bern, 43017-3521, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Feb 2028, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Apr 18, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2028
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05816382
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Apr 5, 2023
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Mar 5, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oveporexton

Start the discussion